Editas Medicine (EDIT) Depreciation & Amortization (CF) (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Depreciation & Amortization (CF) data on file, last reported at $721000.0 in Q3 2025.

• On a quarterly basis, Depreciation & Amortization (CF) fell 54.91% year-over-year to $721000.0 in Q3 2025; TTM through Dec 2025 was $4.5 million, a 22.9% decrease from a year earlier, with the FY2024 full-year figure at $5.8 million, down 4.92% from the prior year.
• Depreciation & Amortization (CF) for Q3 2025 stood at $721000.0, down from $1.8 million in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for EDIT reached as high as $1.9 million in Q1 2025 and fell as low as $721000.0 in Q3 2025.
• Historically, Depreciation & Amortization (CF) has averaged $1.5 million across 5 years, with a median of $1.5 million in 2023.
• Across the five-year window, Depreciation & Amortization (CF) surged 45.74% in 2021 and slumped 54.91% in 2025, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $1.6 million in 2021, then advanced by 1.22% to $1.6 million in 2022, then slipped by 4.76% to $1.5 million in 2023, then declined by 8.66% to $1.4 million in 2024, then plunged by 47.45% to $721000.0 in 2025.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $721000.0 in Q3 2025, $1.8 million in Q2 2025, and $1.9 million in Q1 2025.